HAL will be down for maintenance from Friday, June 10 at 4pm through Monday, June 13 at 9am. More information
Skip to Main content Skip to Navigation
Journal articles

2020, A Decisive Decade for NADPH Oxidases Inhibitors

Abstract : NADPH oxidases (Noxs) represent an original pharmacological target because they are the only enzymes whose main function is to produce reactive oxygen species. It is also a double target with the need for stimulation in chronic granulomatosis and inhibition reported in other pathologies (vascular, cancerous, neurological, etc.). The complexity of the involvement of Noxs in pathophysiology has not yet made it possible to obtain a drug that effectively inhibits these enzymes at the clinical level. This issue of the Forum aims to take stock of the obstacles and limitations to the development of these inhibitors both in their preclinical and clinical evaluation.
Complete list of metadata

Contributor : Ludovic Leloup Connect in order to contact the contributor
Submitted on : Friday, October 23, 2020 - 9:18:24 AM
Last modification on : Wednesday, November 3, 2021 - 9:56:26 AM



Hervé Kovacic. 2020, A Decisive Decade for NADPH Oxidases Inhibitors. Antioxidants and Redox Signaling, Mary Ann Liebert, 2020, 33 (5), pp.329-331. ⟨10.1089/ars.2020.8069⟩. ⟨hal-02975872⟩



Record views